A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.

Fracasso PM, Goodner SA, Wildi JD, Naughton MJ, Linette GP, Govindan R, Tan BR, Blum KA, Jones GJ, Pearce TE, Levitt DJ, Clamon GH

Open source

DOI: 10.1097/coc.0000000000000924
Published: 2022 Jul 1
Container: American journal of clinical oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/coc.0000000000000924,
  title = {A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.},
  author = {Fracasso PM and Goodner SA and Wildi JD and Naughton MJ and Linette GP and Govindan R and Tan BR and Blum KA and Jones GJ and Pearce TE and Levitt DJ and Clamon GH},
  year = {2022},
  journal = {American journal of clinical oncology},
  doi = {10.1097/coc.0000000000000924},
  url = {https://doi.org/10.1097/coc.0000000000000924}
}

RIS

TY  - JOUR
TI  - A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.
AU  - Fracasso PM
AU  - Goodner SA
AU  - Wildi JD
AU  - Naughton MJ
AU  - Linette GP
AU  - Govindan R
AU  - Tan BR
AU  - Blum KA
AU  - Jones GJ
AU  - Pearce TE
AU  - Levitt DJ
AU  - Clamon GH
PY  - 2022
JO  - American journal of clinical oncology
DO  - 10.1097/coc.0000000000000924
UR  - https://doi.org/10.1097/coc.0000000000000924
ER  -

APA

PM, F., SA, G., JD, W., MJ, N., GP, L., R, G., BR, T., KA, B., GJ, J., TE, P., DJ, L., & GH, C. (2022). A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.. American journal of clinical oncology. https://doi.org/10.1097/coc.0000000000000924

Source records

pubmed · retrieved 2026-09-26T18:24:59.941Z